Principles of Immunophenotyping

Hematopathology

Volumn , Issue , 2008, Pages 27-55

  Naeim, Faramarz ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871412885     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-370607-2.00002-8     Document Type: Chapter

References (198)

1. Zola H, Swart B The human leucocyte differentiation antigens (HLDA) workshops: The evolving role of antibodies in research, diagnosis and therapy. Cell Res 2005, 15:691-694.
2. Swart B, Salganik MP, Wand MP, Tinckam K, Milford EL, Drbal K, Angelisova P, Horejsi V, Macardle P, Bailey S, Hollemweguer E, Hodge G, Nairn J, Millard D, Dagdeviren A, Dandie GW, Zola H HLDA8 blind panel. The HLDA8 blind panel: Findings and conclusions. J Immunol Methods 2005, 305:75-83.
3. Zola H, Swart B, Nicholson I, Aasted B, Bensussan A, Boumsell L, Buckley C, Clark G, Drbal K, Engel P, Hart D, Horejsi V, Isacke C, Macardle P, Malavasi F, Mason D, Olive D, Saalmueller A, Schlossman SF, Schwartz-Albiez R, Simmons P, Tedder TF, Uguccioni M, Warren H CD molecules 2005: Human cell differentiation molecules. Blood 2005, 106:3123-3126.
4. Naeim F Pathology of Bone Marrow 1997, Williams & Wilkins, Baltimore. 2nd ed.
5. Knowles DM Neoplastic Hematopathology 2000, Lippincott Williams & Wilkins, Philadelphia. 2nd ed.
6. Jaffe ES, Harris NL, Stein H, Vardiman JW Pathology and Genetics. Tumors of Haematopoietic and Lymphoid Tissues 2001, IARC Press, Lyon.
7. Human Cell Differentiation Molecules. Web site: . http://www.hlda8.org.
8. Arber DA, Weiss LM CD10: A review. Appl Immunohistochem Mol Morphol 1997, 5:125-140.
9. Avery AK, Beckstead J, Renshaw AA, Corless CL Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 2000, 24:203-210.
10. Mazal PR, Stichenwirth M, Koller A, Blach S, Haitel A, Susani M Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: A tissue microarray study. Mod Pathol 2005, 18:535-540.
11. Carter RH, Tuveson DA, Park DJ, Rhee SG, Fearon DT The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J Immunol 1991, 147:3663-3671.
12. Murakami T, Chen X, Hase K, Sakamoto A, Nishigaki C, Ohno H Splenic CD19-CD35+B220+ cells function as an inducer of follicular dendritic cell network formation. Blood 2007, 110:1215-1224.
13. Macardle PJ, Nicholson IC CD20. J Biol Regul Homeost Agents 2002, 16:136-138.
14. Prota AE, Sage DR, Stehle T, Fingeroth JD The crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding. Proc Natl Acad Sci U S A 2002, 99:10641-10646.
15. Liu YJ, Xu J, de Bouteiller O, Parham CL, Grouard G, Djossou O, de Saint-Vis B, Lebecque S, Banchereau J, Moore KW Follicular dendritic cells specifically express the long CR2/CD21 isoform. J Exp Med 1997, 185:165-170.
16. Doody GM, Justement LB, Delibrias CC, Matthews RJ, Lin J, Thomas ML, Fearon DT A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 1995, 269:242-244.
17. Kelm S, Gerlach J, Brossmer R, Danzer CP, Nitschke L The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J Exp Med 2002, 195:1207-1213.
18. Huang J, Fan G, Zhong Y, Gatter K, Braziel R, Gross G, Bakke A Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry. Am J Clin Pathol 2005, 127:826-832.
19. Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY CD21 is a ligand for CD23 and regulates IgE production. Nature 1992, 358:505-507.
20. Tu Y, Salim S, Bourgeois J, Di Leo V, Irvine EJ, Marshall JK, Perdue MH CD23-mediated IgE transport across human intestinal epithelium: Inhibition by blocking sites of translation or binding. Gastroenterology 2005, 129:928-940.
21. DiRaimondo F, Albitar M, Huh Y, O'Brien S, Montillo M, Tedeschi A, Kantarjian H, Lerner S, Giustolisi R, Keating M The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer 2002, 94:1721-1730.
22. Lim SC, Oh SH The role of CD24 in various human epithelial neoplasias. Pathol Res Pract 2005, 201:479-486.
23. Chu PG, Arber DA CD79: A review. Appl Immunohistochem Mol Morphol 2001, 9:97-106.
24. Schlette E, Medeiros LJ, Keating M, Lai R CD79b expression in chronic lymphocytic leukemia. Association with trisomy 12 and atypical immunophenotype. Arch Pathol Lab Med 2003, 127:561-566.
25. Bhargava P, Kallakury BV, Ross JS, Azumi N, Bagg A CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone-dependent manner. Am J Clin Pathol 2007, 128:306-313.
26. He G, Wu D, Sun A, Xue Y, Jin Z, Qiu H, Miao M, Tang X, Fu Z, Chen Z CytCD79a expression in acute leukemia with t(8;21): Biphenotypic or myeloid leukemia?. Cancer Genet Cytogenet 2007, 174:76-77.
27. Wijdenes J, Dore JM, Clement C, Vermot-Desroches C CD138. J Biol Regul Homeost Agents 2002, 6:152-155.
28. Kambham N, Kong C, Longacre TA, Natkunam Y Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: A tissue microarray study of 1,754 cases. Appl Immunohistochem Mol Morphol 2005, 13:304-310.
29. Braylan RC, Orfao A, Borowitz MJ, Davis BH Optimal number of reagents required to evaluate hematolymphoid neoplasias: Results of an international consensus meeting. Cytometry 2001, 46:23-27.
30. Koch N, Moldenhauer G, Hofmann WJ, Moller P Rapid intracellular pathway gives rise to cell surface expression of the MHC class II-associated invariant chain (CD74). J Immunol 1991, 147:2643-2651.
31. Badve S, Deshpande C, Hua Z, Logdberg L Expression of invariant chain (CD74) and major histocompatibility complex (MHC) class II antigens in the human fetus. J Histochem Cytochem 2004, 50:473-482.
32. Moller P, Moldenhauer G CD74. J Biol Regul Homeost Agents 2000, 14:299-301.
33. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, Goldenberg DM CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004, 10:6606-6611.
34. Oshitani N, Watanabe K, Maeda K, Fujiwara Y, Higuchi K, Matsumoto T, Arakawa T Differential expression of homing receptor CD103 on lamina propria lymphocytes and association of CD103 with epithelial adhesion molecules in inflammatory bowel disease. Int J Mol Med 2003, 12:715-719.
35. Chen YH, Tallman MS, Goolsby C, Peterson L Immunophenotypic variations in hairy cell leukemia. Am J Clin Pathol 2006, 125:1-9.
36. Babusikova O, Tomova A Hairy cell leukemia: Early immunophenotypical detection and quantitative analysis by flow cytometry. Neoplasma 2003, 50:350-356.
37. Serke S, Schwaner I, Yordanova M, Szczepek A, Huhn D Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: Evidence from phenotyping after rituxan therapy and transfectant cell analyses. Cytometry 2001, 46:98-104.
38. Ahmad E, Garcia D, Davis BH Clinical utility of CD23 and FMC7 antigen coexistent expression in B-cell lymphoproliferative disorder subclassification. Cytometry 2002, 50:1-7.
39. Delgado J, Matutes E, Morilla AM, Morilla RM, Owusu-Ankomah KA, Rafiq-Mohammed F, del Giudice I, Catovsky D Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. Am J Clin Pathol 2003, 120:754-759.
40. Vincent MS, Xiong X, Grant EP, Peng W, Brenner MB CD1a-, b-, and c-restricted TCRs recognize both self and foreign antigens. J Immunol 2005, 175:6344-6351.
41. Hunger RE, Sieling PA, Ochoa MT, Sugaya M, Burdick AE, Rea TH, Brennan PJ, Belisle JT, Blauvelt A, Porcelli SA, Modlin RL Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. J Clin Invest 2004, 113:701-708.
42. Coventry B, Heinzel S CD1a in human cancers: A new role for an old molecule. Trends Immunol 2004, 25:242-248.
43. Salamone MC, Roisman FR, Santiago J, Satz ML, Fainboim L Analysis of CD1 molecules on haematological malignancies of myeloid and lymphoid origin. I. Cell surface antigen expression. Dis Markers 1990, 8:265-269.
44. Yang JJ, Ye Y, Carroll A, Yang W, Lee HW Structural biology of the cell adhesion protein CD2: Alternatively folded states and structure-function relation. Curr Protein Pept Sci 2001, 2:1-17.
45. Kim M, Sun ZY, Byron O, Campbell G, Wagner G, Wang J, Reinherz EL Molecular dissection of the CD2-CD58 counter-receptor interface identifies CD2 Tyr86 and CD58 Lys34 residues as the functional "hot spot". J Mol Biol 2001, 312:711-720.
46. Moingeon P, Chang HC, Sayre PH, Clayton LK, Alcover A, Gardner P, Reinherz EL The structural biology of CD2. Immunol Rev 1989, 111:111-144.
47. Kastrup J, Pedersen LO, Dietrich J, Lauritsen JP, Menne C, Geisler C In vitro production and characterization of partly assembled human CD3 complexes. Scand J Immunol 2003, 56:436-442.
48. Gaubin M, Autiero M, Houlgatte R, Basmaciogullari S, Auffray C, Piatier-Tonneau D Molecular basis of T lymphocyte CD4 antigen functions. Eur J Clin Chem Clin Biochem 1996, 34:723-728.
49. Nakamura K, Yube K, Miyatake A, Cambier JC, Hirashima M Involvement of CD4 D3-D4 membrane proximal extracellular domain for the inhibitory effect of oxidative stress on activation-induced CD4 down-regulation and its possible role for T cell activation. Mol Immunol 2003, 39:909-921.
50. Sattentau QJ, Weiss RA The CD4 antigen: Physiological ligand and HIV receptor. Cell 1988, 52:631-633.
51. Raab M, Yamamoto M, Rudd CE The T-cell antigen CD5 acts as a receptor and substrate for the protein-tyrosine kinase p56lck. Mol Cell Biol 1994, 14:2862-2870.
52. Tarakhovsky A, Kanner SB, Hombach J, Ledbetter JA, Muller W, Killeen N, Rajewsky K A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science 1995, 269:535-537.
53. Perez-Chacon G, Contreras-Martin B, Cuni S, Rosado S, Martin-Donaire T, Losada-Fernandez I, Vargas JA, Jorda J, Alvarez N, Garcia-Marco J, Perez-Aciego P Polymorphism in the CD5 gene promoter in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Am J Clin Pathol 2005, 123:646-650.
54. Stillwell R, Bierer BE T cell signal transduction and the role of CD7 in costimulation. Immunol Res 2001, 24:31-52.
55. Cruse JM, Lewis RE, Pierce S, Lam J, Tadros Y Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp Mol Pathol 2005, 79:39-41.
56. Laky K, Fleischacker C, Fowlkes BJ TCR and Notch signaling in CD4 and CD8 T-cell development. Immunol Rev 2006, 209:274-283.
57. Schepers K, Arens R, Schumacher TN Dissection of cytotoxic and helper T cell responses. Cell Mol Life Sci 2005, 62:2695-2710.
58. Pilarski LM, Deans JP Selective expression of CD45 isoforms and of maturation antigens during human thymocyte differentiation: Observations and hypothesis. Immunol Lett 1989, 21:187-198.
59. Beverley PC Human T cell subsets. Immunol Lett 1987, 14:263-267.
60. Bell EB Function of CD4 T cell subsets in vivo: Expression of CD45R isoforms. Semin Immunol 1992, 4:43-50.
61. Mahajan VS, Leskov IB, Chen JZ Homeostasis of T cell diversity. Cell Mol Immunol 2005, 2:1-10.
62. Carreno LJ, Gonzalez PA, Kalergis AM Modulation of T cell function by TCR/pMHC binding kinetics. Immunobiology 2006, 211:47-64.
63. Girardi M Immunosurveillance and immunoregulation by gamma delta T cells. J Invest Dermatol 2006, 126:25-31.
64. Ohnuma K, Inoue H, Uchiyama M, Yamochi T, Hosono O, Dang NH, Morimoto C T-cell activation via CD26 and caveolin-1 in rheumatoid synovium. Mod Rheumatol 2006, 16:3-13.
65. Hegen M, Kameoka J, Dong RP, Morimoto C, Schlossman SF Structure of CD26 (dipeptidyl peptidase IV) and function in human T cell activation. Adv Exp Med Biol 1997, 421:109-116.
66. Introcaso CE, Hess SD, Kamoun M, Ubriani R, Gelfand JM, Rook AH Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sezary syndrome. J Am Acad Dermatol 2005, 53:428-434.
67. Pulford K, Lamant L, Espinos E, Jiang Q, Xue L, Turturro F, Delsol G, Morris SW The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci 2004, 61:2939-2953.
68. Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, Kosmatopoulos K, Gambacorti-Passerini C ALK as a novel lymphoma-associated tumor antigen: Identification of 2 HLA-A2.1-restricted CD8+T-cell epitopes. Blood 2002, 99:2100-2106.
69. Housden HR, Skipp PJ, Crump MP, Broadbridge RJ, Crabbe T, Perry MJ, Gore MG Investigation of the kinetics and order of tyrosine phosphorylation in the T-cell receptor zeta chain by the protein tyrosine kinase Lck. Eur J Biochem 2003, 270:2369-2376.
70. Sun PD Structure and function of natural-killer-cell receptors. Immunol Res 2003, 27:539-548.
71. Shibuya A Development and functions of natural killer cells. Int J Hematol 2003, 78:1-6.
72. Stroncek D Neutrophil alloantigens. Transfus Med Rev 2002, 16:67-75.
73. Edberg JC, Salmon JE, Kimberly RP Functional capacity of Fc gamma receptor III (CD16) on human neutrophils. Immunol Res 1992, 11:239-251.
74. Thomason RW, Papiez J, Lee RV, Szczarkowski W Identification of unsuspected PNH-type cells in flow cytometric immunophenotypic analysis of peripheral blood and bone marrow. Am J Clin Pathol 2004, 22:128-134.
75. Olteanu H, Karandikar NJ, McKenna RW, Xu Y Differential usefulness of various markers in the flow cytometric detection of paroxysmal nocturnal hemoglobinuria in blood and bone marrow. Am J Clin Pathol 2006, 126:781-788.
76. Lanier LL, Cwirla S, Yu G, Testi R, Phillips JH Membrane anchoring of a human IgG Fc receptor (CD16) determined by a single amino acid. Science 1989, 246:1611-1613.
77. Lanier LL, Testi R, Bindl J, Phillips JH Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989, 169:2233-2238.
78. Lanier LL Back to the future - defining NK cells and T cells. Eur J Immunol 2007, 37:1424-1426.
79. Batoni G, Esin S, Favilli F, Pardini M, Bottai D, Maisetta G, Florio W, Campa M Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guerin. Scand J Immunol 2005, 62:498-506.
80. Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M, Meijer CJ, Courville P, Joly P, Grange F, DeMuret A, Machet L, Dompmartin A, Bosq J, Durlach A, Bernard P, Dalac S, Dechelotte P, D'Incan M, Wechsler J, Teitell MA Blastic NK-cell lymphomas (agranular CD4+CD56+hematodermic neoplasms): A review. Am J Clin Pathol 2005, 123:662-675.
81. Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O'Brien S, Faderl S, Kantarjian HM CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res 2002, 26:643-649.
82. Kurokawa M, Nabeshima K, Akiyama Y, Maeda S, Nishida T, Nakayama F, Amano M, Ogata K, Setoyama M CD56: A useful marker for diagnosing Merkel cell carcinoma. J Dermatol Sci 2003, 31:219-224.
83. Ibegbu CC, Xu YX, Harris W, Maggio D, Miller JD, Kourtis AP Expression of killer cell lectin-like receptor G1 on antigen-specific human CD8+T lymphocytes during active, latent, and resolved infection and its relation with CD57. J Immunol 2005, 174:6088-6094.
84. Rose MG, Berliner N T-cell large granular lymphocyte leukemia and related disorders. Oncologist 2004, 9:247-258.
85. Tarazona R, DelaRosa O, Alonso C, Ostos B, Espejo J, Peña J, Solana R. Increased expression of NK cell markers on T-lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T-cells. Mech Ageing Dev 2000, 121:77-88.
86. Ng SB, Sirrampalam K, Chuah KL Primitive neuroectodermal tumours of the uterus: A case report with cytological correlation and review of the literature. Pathology 2002, 34:455-461.
87. Lanier LL NK cell receptors. Annu Rev Immunol 1998, 16:359-393.
88. Long EO, Barber DF, Burshtyn DN, Faure M, Peterson M, Rajagopalan S, Renard V, Sandusky M, Stebbins CC, Wagtmann N, Watzl C Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158). Immunol Rev 2001, 181:223-233.
89. Metelitsa LS Flow cytometry for natural killer T cells: Multi-parameter methods for multifunctional cells. Clin Immunol 2004, 110:267-276.
90. McQueen KL, Parham P Variable receptors controlling activation and inhibition of NK cells. Curr Opin Immunol 2002, 14:615-621.
91. Poggi A, Massaro AM, Negrini S, Contini P, Zocchi MR Tumor-induced apoptosis of human IL-2-activated NK cells: Role of natural cytotoxicity receptors. J Immunol 2005, 174:2653-2660.
92. Augugliaro R, Parolini S, Castriconi R, Marcenaro E, Cantoni C, Nanni M, Moretta L, Moretta A, Bottino C Selective cross-talk among natural cytotoxicity receptors in human natural killer cells. Eur J Immunol 2003, 33:1235-1241.
93. Poggi A, Prevosto C, Massaro AM, Negrini S, Urbani S, Pierri I, Saccardi R, Gobbi M, Zocchi MR Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: Role of NKp30 and NKG2D receptors. J Immunol 2005, 175:6352-6360.
94. Luan Y, Xu W The structure and main functions of aminopeptidase N. Curr Med Chem 2007, 14:639-647.
95. Mason KD, Juneja SK, Szer J The immunophenotype of acute myeloid leukemia: Is there a relationship with prognosis?. Blood Rev 2006, 20:71-82.
96. Asahara SI, Saigo K, Hasuike N, Tamura M, Maeda Y, Tomofuji Y, Chinzei T, Tatsumi E Acute lymphoblastic leukemia accompanied by chromosomal abnormality of translocation (12;17). Haematologia (Budap) 2001, 31:209-213.
97. Andra J, Gutsmann T, Garidel P, Brandenburg K Mechanisms of endotoxin neutralization by synthetic cationic compounds. J Endotoxin Res 2006, 12:261-277.
98. Jersmann HP Time to abandon dogma: CD14 is expressed by non-myeloid lineage cells. Immunol Cell Biol 2005, 83:462-467.
99. Sutherland DR, Kuek N, Davidson J, Barth D, Chang H, Yeo E, Bamford S, Chin-Yee I, Keeney M Diagnosing PNH with FLAER and multiparameter flow cytometry. Cytometry B Clin Cytom 2007, 72:167-177.
100. Gocht A, Struckhoff G, Lhler J CD15-containing glycoconjugates in the central nervous system. Histol Histopathol 1996, 11:1007-1028.
101. Comin CE, Novelli L, Boddi V, Paglierani M, Dini S Calretinin, thrombomodulin, CEA, and CD15: A useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 2001, 32:529-536.
102. Rudiger T, Ott G, Ott MM, Muller-Deubert SM, Muller-Hermelink HK Differential diagnosis between classic Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry. Am J Surg Pathol 1998, 22:1184-1191.
103. Andrews RG, Torok-Storb B, Bernstein ID Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 1983, 62:124-132.
104. Wellhausen SR, Peiper SC CD33: Biochemical and biological characterization and evaluation of clinical relevance. J Biol Regul Homeost Agents 2002, 16:139-143.
105. Cohen-Solal JF, Cassard L, Fridman WH, Sautes-Fridman C Fc gamma receptors. Immunol Lett 2004, 92:199-205.
106. Davis BH, Bigelow NC Comparison of neutrophil CD64 expression, manual myeloid immaturity counts, and automated hematology analyzer flags as indicators of infection or sepsis. Lab Hematol 2005, 11:137-147.
107. Fjaertoft G, Hakansson L, Foucard T, Ewald U, Venge P CD64 (Fcgamma receptor I) cell surface expression on maturing neutrophils from preterm and term newborn infants. Acta Paediatr 2005, 94:295-302.
108. Holness CL, Simmons DL Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 1993, 81:1607-1613.
109. Pulford KA, Sipos A, Cordell JL, Stross WP, Mason DY Distribution of the CD68 macrophage/myeloid associated antigen. Int Immuno 1990, 12:973-980.
110. Re F, Arpinati M, Testoni N, Ricci P, Terragna C, Preda P, Ruggeri D, Senese B, Chirumbolo G, Martelli V, Urbini B, Baccarani M, Tura S, Rondelli D Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. Exp Hematol 2002, 30:126-134.
111. Svec A, Velenska Z Renal epithelioid angiomyolipoma - a close mimic of renal cell carcinoma. Report of a case and review of the literature. Pathol Res Pract 2005, 200:851-856.
112. Wojta J, Kaun C, Zorn G, Ghannadan M, Hauswirth AW, Sperr WR, Fritsch G, Printz D, Binder BR, Schatzl G, Zwirner J, Maurer G, Huber K, Valent P C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 2002, 100:517-523.
113. Hauswirth AW, Florian S, Schernthaner GH, Krauth MT, Sonneck K, Sperr WR, Valent P Expression of cell surface antigens on mast cells: Mast cell phenotyping. Methods Mol Biol 2006, 315:77-90.
114. Sampson M, Zhu QS, Corey SJ Src kinases in G-CSF receptor signaling. Front Biosci 2007, 12:1463-1474.
115. Avalos BR Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 1996, 88:761-777.
116. Tsuji K, Ebihara Y Expression of G-CSF receptor on myeloid progenitors. Leuk Lymphoma 2001, 42:1351-1357.
117. Touw IP, van de Geijn GJ Granulocyte colony-stimulating factor and its receptor in normal myeloid cell development, leukemia and related blood cell disorders. Front Biosci 2007, 12:800-815.
118. Calhoun DA, Donnelly WH, Du Y, Dame JB, Li Y, Christensen RD Distribution of granulocyte colony-stimulating factor (G-CSF) and G-CSF-receptor mRNA and protein in the human fetus. Pediatr Res 1999, 46:333-338.
119. Pixley FJ, Stanley ER CSF-1 regulation of the wandering macrophage: Complexity in action. Trends Cell Biol 2004, 14:628-638.
120. Dabusti M, Castagnari B, Moretti S, Ferrari L, Tieghi A, Lanza F CD116 (granulocyte-macrophage colony stimulating factor receptor). J Biol Regul Homeost Agents 2001, 15:86-89.
121. Baum J, Ward RH, Conway DJ Natural selection on the erythrocyte surface. Mol Biol Evol 2002, 19:223-229.
122. Lisowska E Antigenic properties of human glycophorins - an update. Adv Exp Med Biol 2001, 491:155-169.
123. Palacajornsuk P Review: Molecular basis of MNS blood group variants. Immunohematology 2006, 22:171-182.
124. Nakahata T, Okumura N Cell surface antigen expression in human erythroid progenitors: Erythroid and megakaryocytic markers. Leuk Lymphoma 1994, 13:401-409.
125. Daniels G The molecular genetics of blood group polymorphism. Transpl Immunol 2005, 14:143-153.
126. Wagner FF, Flegel WA Review: The molecular basis of the Rh blood group phenotypes. Immunohematology 2004, 20:23-36.
127. Hermand P, Gane P, Huet M, Jallu V, Kaplan C, Sonneborn HH, Cartron JP, Bailly P Red cell ICAM-4 is a novel ligand for platelet-activated alpha IIbbeta 3 integrin. J Biol Chem 2003, 278:4892-4898.
128. Aisen P Transferrin receptor 1. Int J Biochem Cell Biol 2004, 36:2137-2143.
129. Miller JL A genome-based approach for the study of erythroid biology and disease. Blood Cells Mol Dis 2004, 3:341-343.
130. Slupsky JR, Kamiguti AS, Rhodes NP, Cawley JC, Shaw AR, Zuzel M The platelet antigens CD9, CD42 and integrin alpha IIb beta IIIa can be topographically associated and transduce functionally similar signals. Eur J Biochem 1997, 244:168-175.
131. Clemetson KJ, Clemetson JM Molecular abnormalities in Glanzmann's thrombasthenia, Bernard-Soulier syndrome, and platelet-type von Willebrand's disease. Curr Opin Hematol 1994, 1:388-393.
132. Gassmann W, Loffler H Acute megakaryoblastic leukemia. Leuk Lymphoma 1995, 18(Suppl 1):69-73.
133. Bennett JS Structure and function of the platelet integrin alphaIIbbeta3. J Clin Invest 2004, 115:3363-3369.
134. Fullard JF The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr Pharm Des 2004, 10:1567-1576.
135. Fishley B, Alexander WS Thrombopoietin signalling in physiology and disease. Growth Factors 2004, 22:151-155.
136. Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Luthra PM Hematopoietic stem cell antigen CD34: Role in adhesion or homing. Stem Cells Dev 2006, 15:305-313.
137. Krause DS, Fackler MJ, Civin CI, May WS CD34: Structure biology, and clinical utility. Blood 1996, 8:1-13.
138. Florian S, Sonneck K, Hauswirth AW, Krauth MT, Schernthaner GH, Sperr WR, Valent P Detection of molecular targets on the surface of CD34+/CD382 stem cells in various myeloid malignancies. Leuk Lymphoma 2006, 47:207-222.
139. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blai A Characterization of acute lymphoblastic leukemia progenitor cells. Blood 2004, 104:2919-2925.
140. Deaglio S, Dianzani U, Horenstein AL, Fernandez JE, van Kooten C, Bragardo M, Funaro A, Garbarino G, Di Virgilio F, Banchereau J, Malavasi F Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells. J Immunol 1996, 156:727-734.
141. Lee HC Enzymatic functions and structures of CD38 and homologs. Chem Immunol 2000, 75:39-59.
142. Malavasi F, Funaro A, Alessio M, DeMonte LB, Ausiello CM, Dianzani U, Lanza F, Magrini E, Momo M, Roggero S CD38: A multi-lineage cell activation molecule with a split personality. Int J Clin Lab Res 1992, 22:73-80.
143. Costello R, Sainty D, Bouabdallah R, Fermand JP, Delmer A, Divine M, Marolleau JP, Gastaut JA, Olive D, Rousselot P, Chaibi P Primary plasma cell leukaemia: A report of 18 cases. Leuk Res 2001, 25:103-107.
144. Henniker AJ CD90. J Biol Regul Homeost Agents 2001, 15:392-393.
145. Wetzel A, Chavakis T, Preissner KT, Sticherling M, Haustein UF, Anderegg U, Saalbach A Human Thy-1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Immunol 2004, 172:3850-3859.
146. Kang LC, Dunphy CH Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes. Arch Pathol Lab Med 2006, 130:153-157.
147. Dworzak MN, Froschl G, Printz D, Zen LD, Gaipa G, Ratei R, Basso G, Biondi A, Ludwig WD, Gadner H CD99 expression in T-lineage ALL: Implications for flow cytometric detection of minimal residual disease. Leukemia 2004, 18:703-708.
148. Khoury JD Ewing sarcoma family of tumors. Adv Anat Pathol 2005, 12:212-220.
149. Galli SJ, Zsebo KM, Geissler EN The kit ligand, stem cell factor. Adv Immunol 1994, 55:1-96.
150. Lugli A, Went P, Khanlari B, Nikolova Z, Dirnhofer S Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment. Virchows Arch 2004, 444:264-268.
151. Wozniak J, Kopec-Szlezak J c-Kit receptor (CD117) expression on myeloblasts and white blood cell counts in acute myeloid leukemia. Cytometry B Clin Cytom 2004, 58:9-16.
152. Scolnik MP, Morilla R, de Bracco MM, Catovsky D, Matutes E CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease. Leuk Res 2002, 26:615-619.
153. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L, REMA. (2007). Recent advances in the understanding of mastocytosis: The role of KIT mutations. Br J Haematol38, 12-30.
154. Drexler HG, Sperling C, Ludwig WD Terminal deoxynucleotidyl transferase (TdT) expression in acute myeloid leukemia. Leukemia 1993, 7:1142-1150.
155. Ihanus E, Uotila L, Toivanen A, Stefanidakis M, Bailly P, Cartron JP, Gahmberg CG Characterization of ICAM-4 binding to the I domains of the CD11a/CD18 and CD11b/CD18 leukocyte integrins. Eur J Biochem 2003, 270:1710-1723.
156. Gruss HJ Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clin Lab Res 1996, 26:143-159.
157. Schneider C, Hubinger G Pleiotropic signal transduction mediated by human CD30: A member of the tumor necrosis factor receptor (TNFR) family. Leuk Lymphoma 2002, 43:1355-1366.
158. Gruss HJ, Dower SK Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas. Blood 1995, 85:3378-3404.
159. Cossu-Rocca P, Jones TD, Roth LM, Eble JN, Zheng W, Karim FW, Cheng L Cytokeratin and CD30 expression in dysgerminoma. Hum Pathol 2006, 37:1015-1021.
160. Rakheja D, Hoang MP, Sharma S, Albores-Saavedra J Intratubular embryonal carcinoma. Arch Pathol Lab Med 2002, 126:487-490.
161. Rosenstein Y, Santana A, Pedraza-Alva G CD43, a molecule with multiple functions. Immunol Res 1999, 20:89-99.
162. Remold-O'Donnell E, Rosen FS Sialophorin (CD43) and the Wiskott-Aldrich syndrome. Immunodefic Rev 1990, 2:151-174.
163. Greer WL, Higgins E, Sutherland DR, Novogrodsky A, Brockhausen I, Peacocke M, Rubin LA, Baker M, Dennis JW, Siminovitch KA Altered expression of leucocyte sialoglycoprotein in Wiskott-Aldrich syndrome is associated with a specific defect in O-glycosylation. Biochem Cell Biol 1989, 67:503-509.
164. Harris CL, Abbott RJ, Smith RA, Morgan BP, Lea SM Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). J Biol Chem 2005, 280:2569-2578.
165. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, Hillmen P, Luzzatto L, Young N, Kinoshita T, Rosse W, Socie G Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005, 106:3699-3709. International PNH Interest Group, Epub 2005 Jul 28.
166. Krauss JS Laboratory diagnosis of paroxysmal nocturnal hemoglobinuria. Ann Clin Lab Sci 2003, 33:401-406. Review.
167. Maio M, Brasoveanu LI, Coral S, Sigalotti L, Lamaj E, Gasparollo A, Visintin A, Altomonte M, Fonsatti E Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies. Int J Oncol 1998, 13:305-318.
168. Tachibana KE, Gonzalez MA, Coleman N Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol 2005, 205:123-129.
169. Sheval EV, Churakova JV, Dudnik OA, Vorobjev IA Examination of the proliferative activity of tumor cells in human lymphoid neoplasms using a morphometric approach. Cancer 2004, 102:174-185.
170. Dong HY, Liu W, Cohen P, Mahle CE, Zhang W B-cell specific activation protein encoded by the PAX-5 gene is commonly expressed in merkel cell carcinoma and small cell carcinomas. Am J Surg Pathol 2005, 29:687-692.
171. Maier H, Hagman J Roles of EBF and Pax-5 in B lineage commitment and development. Semin Immunol 2002, 14:415-422.
172. Poppe B, De Paepe P, Michaux L, Dastugue N, Bastard C, Herens C, Moreau E, Cavazzini F, Yigit N, Van Limbergen H, De Paepe A, Praet M, De Wolf-Peeters C, Wlodarska I, Speleman F PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer 2005, 44:218-223.
173. Tiacci E, Pileri S, Orleth A, Pacini R, Tabarrini A, Frenguelli F, Liso A, Diverio D, Lo-Coco F, Falini B PAX5 expression in acute leukemias: Higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res 2004, 64:7399-7404.
174. Browne P, Petrosyan K, Hernandez A, Chan JA The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol 2003, 120:767-777.
175. Pileri SA, Gaidano G, Zinzani PL, Falini B, Gaulard P, Zucca E, Pieri F, Berra E, Sabattini E, Ascani S, Piccioli M, Johnson PW, Giardini R, Pescarmona E, Novero D, Piccaluga PP, Marafioti T, Alonso MA, Cavalli F Primary mediastinal B-cell lymphoma: High frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 2003, 162:243-253.
176. Qian D, Weiss A T cell antigen receptor signal transduction. Curr Opin Cell Biol 1997, 9:205-212.
177. Crespo M, Villamor N, Gine E, Muntanola A, Colomer D, Marafioti T, Jones M, Camos M, Campo E, Montserrat E, Bosch F ZAP-70 Expression in normal Pro/Pre B Cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clin Cancer Res 2006, 12:726-734.
178. Vener C, Gianelli U, Cortelezzi A, Fracchiolla NS, Somalvico F, Savi F, Pasquini MC, Bosari S, Deliliers GL ZAP-70 immunoreactivity is a prognostic marker of disease progression in chronic lymphocytic leukemia. Leuk Lymphoma 2006, 47:245-251.
179. Macey MG Flow Cytometry: Principles and Applications 2007, Humana Press, Totowa.
180. Song S, Naeim F New applications of flow cytometry in cancer diagnosis. Cancer Diagnosis. Current and Future Trends 2004, 199-232. Humana Press, Totowa. R.M. Nakamura, W.W. Grody, J.T. Wu, R.B. Nagle (Eds.).
181. Shapiro HM Practical Flow Cytometry 2003, Wiley, Hoboken. 4th ed.
182. Gorczyca W Flow Cytometry in Neoplastic Hematology 2006, Taylor & Francis, London.
183. Baumgarth N, Roederer M A practical approach to multicolor flow cytometry for immunophenotyping. J Immunol Methods 2000, 243:77-97.
184. McCoy JP Basic principles of flow cytometry. Hematol Oncol Clin North Am 2002, 16:229-243.
185. Schwartz A, Marti GE, Poon R, Gratama JW, Fernandez-Repollet E Standardizing flow cytometry: A classification system of fluorescence standards used for flow cytometry. Cytometry 1998, 33:106-114.
186. Gratama JW, Bolhuis RL, Van't Veer MB Quality control of flow cytometric immunophenotyping of haematological malignancies. Clin Lab Haematol 1999, 21:155-160.
187. Stelzer GT, Marti G, Hurley A, McCoy P, Lovett EJ, Schwartz A U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Standardization and validation of laboratory procedures. Cytometry 1997, 30:214-230.
188. Dabbs D Diagnostic Immunohistochemistry 2006, Churchill Livingstone, London. 2nd ed.
189. Polak JM, Van Noorden S Introduction to Immunocytochemistry 2003, Academic Press, New York. 3rd ed.
190. Jaffe ES Hematopathology: Integration of morphologic features and biologic markers for diagnosis. Mod Pathol 1999, 12:109-115.
191. Myers JD Development and application of immunocytochemical staining techniques: A review. Diagn Cytopathol 1989, 5:318-330.
192. Pettigrew NM Techniques in immunocytochemistry. Application to diagnostic pathology. Arch Pathol Lab Med 1989, 113:641-644.
193. Swanson PE Foundations of immunohistochemistry. A practical review. Am J Clin Pathol 1988, 90:333-339.
194. Shi SR, Cote RJ, Taylor CR Antigen retrieval techniques: Current perspectives. J Histochem Cytochem 2001, 49:931-937.
195. Ramos-Vara JA Technical aspects of immunohistochemistry. Vet Pathol 2005, 42:405-426.
196. Berger U, Bettelheim R, Mansi JL, Easton D, Coombes RC, Neville AM The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol 1988, 90:1-6.
197. Thor A, Viglione MJ, Ohuchi N, Simpson J, Steis R, Cousar J, Lippman M, Kufe DW, Schlom J Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow. Breast Cancer Res Treat 1988, 11:133-145.
198. Beck D, Maritaz O, Gross N, Favrot M, Vultier N, Bailly C, Villa I, Gentilhomme O, Philip T Immunocytochemical detection of neuroblastoma cells infiltrating clinical bone marrow samples. Eur J Pediatr 1988, 147:609-612.